Sanofi’s Tzield Delays Children’s Type 1 Diabetes Progression, But Falls Short On Clinical Impact

Sanofi paid $2.9bn for Tzield and its developer Provention earlier this year, but a mixed readout in its key Phase III study will raise doubts among analysts about its long-term prospects in later-stage patients.